Literature DB >> 12411758

Clinical and neuropathological correlates of apolipoprotein E genotype in dementia with Lewy bodies.

Andrew B Singleton1, Anna Wharton, Kirsty K O'Brien, Matthew P Walker, Ian G McKeith, Clive G Ballard, John O'Brien, Robert H Perry, Paul G Ince, James A Edwardson, Christopher M Morris.   

Abstract

Dementia with Lewy bodies (DLB) represents the second commonest cause of dementia in the elderly following Alzheimer's disease (AD). Whilst the presence of Lewy bodies is essential, DLB shares with AD the presence of senile plaques (SP), but neurofibrillary tangles (NFT) are not a necessary feature. The apolipoprotein E (APO E) epsilon4 allele is the most consistently associated genetic risk factor for AD and has also been shown to associate with DLB. We have therefore analysed the APO E epsilon4 allele in a large series of DLB cases coming to autopsy to: (1) determine if the epsilon4 allele describes a similar risk in DLB development as in AD and (2) determine how APO E epsilon4 allele status correlates with clinical and neuropathological findings in DLB, and in AD, as an indication of the role of APO E in underlying disease biology. Both DLB and AD share an increased epsilon4 allele frequency, though in DLB the epsilon2 allele frequency is not reduced and there is a relative lack of epsilon4 homozygotes. In contrast to previous studies, no association of the epsilon4 allele with age at onset or duration of disease was found in either disorders. In DLB cases, overall a significantly shorter duration of illness was observed when compared with AD cases, though no significant effect of the epsilon4 allele on disease onset or duration was seen. The survival rate was reduced by the presence of the epsilon4 allele in DLB, as with AD. No effect on SP or NFT counts was seen with the epsilon4 allele, though DLB cases showed a lower SP burden in addition to the expected lower NFT counts. This study demonstrates that DLB shares the APO epsilon4 allele with AD as a common risk factor, but that there are differences in the way the epsilon4 allele affects the phenotypic expression of disease. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12411758     DOI: 10.1159/000066022

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  20 in total

1.  APOE ε2 and ε4 influence the susceptibility for Alzheimer's disease but not other dementias.

Authors:  Carlo Lovati; Daniela Galimberti; Diego Albani; Pierluigi Bertora; Eliana Venturelli; Giuliana Cislaghi; Ilaria Guidi; Chiara Fenoglio; Francesca Cortini; Francesca Clerici; Dario Finazzi; Gianluigi Forloni; Elio Scarpini; Claudio Mariani
Journal:  Int J Mol Epidemiol Genet       Date:  2010-04-05

2.  Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease.

Authors:  Jennifer L Whitwell; Stephen D Weigand; Maria M Shiung; Bradley F Boeve; Tanis J Ferman; Glenn E Smith; David S Knopman; Ronald C Petersen; Eduardo E Benarroch; Keith A Josephs; Clifford R Jack
Journal:  Brain       Date:  2007-01-31       Impact factor: 13.501

3.  APOE ε4 increases risk for dementia in pure synucleinopathies.

Authors:  Debby Tsuang; James B Leverenz; Oscar L Lopez; Ronald L Hamilton; David A Bennett; Julie A Schneider; Aron S Buchman; Eric B Larson; Paul K Crane; Jeffrey A Kaye; Patricia Kramer; Randy Woltjer; John Q Trojanowski; Daniel Weintraub; Alice S Chen-Plotkin; David J Irwin; Jacqueline Rick; Gerard D Schellenberg; G Stennis Watson; Walter Kukull; Peter T Nelson; Gregory A Jicha; Janna H Neltner; Doug Galasko; Eliezer Masliah; Joseph F Quinn; Kathryn A Chung; Dora Yearout; Ignacio F Mata; Jia Y Wan; Karen L Edwards; Thomas J Montine; Cyrus P Zabetian
Journal:  JAMA Neurol       Date:  2013-02       Impact factor: 18.302

Review 4.  Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases.

Authors:  David G Coughlin; Howard I Hurtig; David J Irwin
Journal:  Mov Disord       Date:  2019-10-29       Impact factor: 10.338

5.  NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases.

Authors:  Cornelis Blauwendraat; Faraz Faghri; Lasse Pihlstrom; Joshua T Geiger; Alexis Elbaz; Suzanne Lesage; Jean-Christophe Corvol; Patrick May; Aude Nicolas; Yevgeniya Abramzon; Natalie A Murphy; J Raphael Gibbs; Mina Ryten; Raffaele Ferrari; Jose Bras; Rita Guerreiro; Julie Williams; Rebecca Sims; Steven Lubbe; Dena G Hernandez; Kin Y Mok; Laurie Robak; Roy H Campbell; Ekaterina Rogaeva; Bryan J Traynor; Ruth Chia; Sun Ju Chung; John A Hardy; Alexis Brice; Nicholas W Wood; Henry Houlden; Joshua M Shulman; Huw R Morris; Thomas Gasser; Rejko Krüger; Peter Heutink; Manu Sharma; Javier Simón-Sánchez; Mike A Nalls; Andrew B Singleton; Sonja W Scholz
Journal:  Neurobiol Aging       Date:  2017-05-17       Impact factor: 4.673

6.  Function and comorbidities of apolipoprotein e in Alzheimer's disease.

Authors:  Valérie Leduc; Dorothée Domenger; Louis De Beaumont; Daphnée Lalonde; Stéphanie Bélanger-Jasmin; Judes Poirier
Journal:  Int J Alzheimers Dis       Date:  2011-04-05

7.  Apolipoprotein E4 frequencies in a Japanese population with Alzheimer's disease and dementia with Lewy bodies.

Authors:  Seiju Kobayashi; Masaru Tateno; Tae Woo Park; Kumiko Utsumi; Hitoshi Sohma; Yoichi M Ito; Yasuo Kokai; Toshikazu Saito
Journal:  PLoS One       Date:  2011-04-28       Impact factor: 3.240

8.  Assessment of APOE in atypical parkinsonism syndromes.

Authors:  Marya S Sabir; Cornelis Blauwendraat; Sarah Ahmed; Geidy E Serrano; Thomas G Beach; Matthew Perkins; Ann C Rice; Eliezer Masliah; Christopher M Morris; Lasse Pihlstrom; Alexander Pantelyat; Susan M Resnick; Mark R Cookson; Dena G Hernandez; Marilyn Albert; Ted M Dawson; Liana S Rosenthal; Henry Houlden; Olga Pletnikova; Juan Troncoso; Sonja W Scholz
Journal:  Neurobiol Dis       Date:  2019-02-21       Impact factor: 5.996

Review 9.  Dementia with Lewy bodies: disease concept and genetics.

Authors:  Manuel B Graeber; Ulrich Müller
Journal:  Neurogenetics       Date:  2003-07-26       Impact factor: 2.660

10.  Evaluation of annexin A5 as a biomarker for Alzheimer's disease and dementia with lewy bodies.

Authors:  Hitoshi Sohma; Shin-Ichi Imai; Norio Takei; Hirohito Honda; Kyoichi Matsumoto; Kumiko Utsumi; Kayo Matsuki; Eri Hashimoto; Toshikazu Saito; Yasuo Kokai
Journal:  Front Aging Neurosci       Date:  2013-04-05       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.